Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
Document Type
- Journal article (32)
Language
- English (32) (remove)
Keywords
- ischemic stroke (11)
- platelets (4)
- stroke (4)
- B cells (3)
- acute ischemic stroke (3)
- ELISPOT (2)
- Inflammation (2)
- MS (2)
- Stroke (2)
- biomarker (2)
- chronic cerebrovascular disease (2)
- factor XII (2)
- immune cells (2)
- immunohistochemistry (2)
- inflammasome (2)
- lymphocytes (2)
- neuroinflammation (2)
- neutrophils (2)
- predictive value (2)
- relapse (2)
- thrombo-inflammation (2)
- transient middle cerebral artery occlusion (2)
- von Willebrand factor (2)
- Arterial water (1)
- Brain (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Coefficient (1)
- Experimental stroke (1)
- FXII (1)
- Glatiramer acetate (1)
- HMGB1 (1)
- Heart failure (1)
- IL-15 (1)
- MIC ligands (1)
- Magnetic-resonance (1)
- Mice (1)
- Mycobacterium caprae (1)
- Mycobacterium tuberculosis complex (1)
- NETs (1)
- NKG2D (1)
- NKG2D ligands (1)
- NLRP3 (1)
- NOAC (1)
- Neurodegeneration (1)
- Perfusion (1)
- Schlaganfall (1)
- Stim (1)
- T cell activation (1)
- Thrombus (1)
- Troponin (1)
- Tuberkulose (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- accuracy (1)
- adherence (1)
- areas (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- biomarkers (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- blood flow (1)
- blood–brain barrier (1)
- cardiovascular disease (1)
- care tempis (1)
- celiac disease (1)
- cerebral small vessel disease (1)
- cerebrospinal fluid culture (1)
- cerebrovascular diseases (1)
- coagulation (1)
- collagens (1)
- cutting edge (1)
- demography (1)
- dendric cells (1)
- edoxaban (1)
- ejection fraction (1)
- experimental stroke (1)
- expression (1)
- factor XI (1)
- family caregiver (1)
- feasibility (1)
- fosfomycin (1)
- glycoprotein Ib (1)
- glycoprotein VI (1)
- glycoprotein receptor Ib (1)
- guidelines (1)
- hemorrhagic transformation (1)
- histology (1)
- hospitals (1)
- human muscle-cells (1)
- hypercholesterolemia (1)
- idiopathic inflammatory myopathies (1)
- increased risk (1)
- inflammation (1)
- informal care (1)
- integrin α2 (1)
- integrins (1)
- intracranial bleeding (1)
- leukocytes (1)
- lymphokine-activated killer (1)
- mechanical thrombectomy (1)
- mechanisms (1)
- mice impact (1)
- middle cerebral artery occlusion (1)
- monocytes (1)
- mortality (1)
- mouse model (1)
- multiple sclerosis (1)
- non-VKA oral anticoagulants (1)
- occlusion (1)
- outcomes (1)
- pathology section (1)
- pilot project (1)
- platelet activation (1)
- platelet aggregation (1)
- point-of-care echocardiography (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- preclinical research (1)
- prevention (1)
- quality (1)
- receptor (1)
- recombinant tissue-type plasminogen activator (1)
- regulatory T cells (1)
- scale (1)
- secondary infarct growth (1)
- serotonin (1)
- sex addiction (1)
- stroke care (1)
- stroke unit (1)
- systolic dysfunction (1)
- tMCAO (1)
- telemedicine network (1)
- thrombemboli (1)
- thromboemboli (1)
- thromboinflammation (1)
- thrombolysis (1)
- thrombus formation (1)
- time (1)
- transient ischemic attack (1)
- transient middle cerebral artery (1)
- tuberculous meningitis (1)
- tumor immunity (1)
- vitamin K antagonists (1)
- warfarin (1)
Institute
- Neurologische Klinik und Poliklinik (30)
- Institut für Klinische Epidemiologie und Biometrie (7)
- Rudolf-Virchow-Zentrum (5)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (4)
- Institut für Anatomie und Zellbiologie (3)
- Institut für Experimentelle Biomedizin (3)
- Medizinische Klinik und Poliklinik I (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (2)
- Institut für Klinische Biochemie und Pathobiochemie (1)
Background
Ischemic stroke immediately evokes a strong neuro-inflammatory response within the vascular compartment, which contributes to primary infarct development under vessel occlusion as well as further infarct growth despite recanalization, referred to as ischemia/reperfusion injury. Later, in the subacute phase of stroke (beyond day 1 after recanalization), further inflammatory processes within the brain parenchyma follow. Whether this second wave of parenchymal inflammation contributes to an additional/secondary increase in infarct volumes and bears the potential to be pharmacologically targeted remains elusive. We addressed the role of the NLR-family pyrin domain-containing protein 3 (NLRP3) inflammasome in the subacute phase of ischemic stroke.
Methods
Focal cerebral ischemia was induced in C57Bl/6 mice by a 30-min transient middle cerebral artery occlusion (tMCAO). Animals were treated with the NLRP3 inhibitor MCC950 therapeutically 24 h after or prophylactically before tMCAO. Stroke outcome, including infarct size and functional deficits as well as the local inflammatory response, was assessed on day 7 after tMCAO.
Results
Infarct sizes on day 7 after tMCAO decreased about 35% after delayed and about 60% after prophylactic NLRP3 inhibition compared to vehicle. Functionally, pharmacological inhibition of NLRP3 mitigated the local inflammatory response in the ischemic brain as indicated by reduction of infiltrating immune cells and reactive astrogliosis.
Conclusions
Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome—even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke.